Concourse Financial Group Securities, Inc. Belite Bio, Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.52 Billion
Q1 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$37.81 - $48.01 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	BUY	$29.5 - $46.02 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$12.53 - $36.64 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$12.53 - $36.64 $0 - $0	0 New	0 $0
Q2 2023 Aug 10, 2023	BUY	$11.18 - $30.2 $0 - $0	0 New	0 $0

Q1 2023 May 15, 2023	BUY	$25.61 - $33.5 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$25.08 - $33.32 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$22.57 - $44.0 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$8.87 - $34.28 $0 - $0	0 New	0 $0

Others Institutions Holding BLTE

# of Institutions

Shares Held

58.3K

Call Options Held

Put Options Held

View Full List

About BELITE BIO, INC

Ticker BLTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,867,400
Market Cap $1.13B
Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...

More about BLTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account